Literature DB >> 17300163

Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase.

Michel C Maillard1, Roy K Hom, Timothy E Benson, Joseph B Moon, Shumeye Mamo, Michael Bienkowski, Alfredo G Tomasselli, Danielle D Woods, D Bryan Prince, Donna J Paddock, Thomas L Emmons, John A Tucker, Michael S Dappen, Louis Brogley, Eugene D Thorsett, Nancy Jewett, Sukanto Sinha, Varghese John.   

Abstract

The design and synthesis of a novel series of potent and cell permeable peptidomimetic inhibitors of the human beta-secretase (BACE) are described. These inhibitors feature a hydroxyethyl secondary amine isostere and a novel aromatic ring replacement for the C-terminus. The crystal structure of BACE in complex with this hydroxyethyl secondary amine isostere inhibitor is also presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300163     DOI: 10.1021/jm061242y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.

Authors:  Arun K Ghosh; Nagaswamy Kumaragurubaran; Lin Hong; Sarang Kulkarni; Xiaoming Xu; Heather B Miller; Dandepally Srinivasa Reddy; Vajira Weerasena; Robert Turner; Wanpin Chang; Gerald Koelsch; Jordan Tang
Journal:  Bioorg Med Chem Lett       Date:  2008-01-03       Impact factor: 2.823

2.  Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands.

Authors:  Arun K Ghosh; Margherita Brindisi; Yu-Chen Yen; Emilio L Cárdenas; Jean-Rene Ella-Menye; Nagaswamy Kumaragurubaran; Xiangping Huang; Jordan Tang; Andrew D Mesecar
Journal:  Bioorg Med Chem Lett       Date:  2017-04-08       Impact factor: 2.823

3.  Targets for AD treatment: conflicting messages from γ-secretase inhibitors.

Authors:  Kumar Sambamurti; Nigel H Greig; Tadanobu Utsuki; Eliza L Barnwell; Ekta Sharma; Cheryl Mazell; Narayan R Bhat; Mark S Kindy; Debomoy K Lahiri; Miguel A Pappolla
Journal:  J Neurochem       Date:  2011-03-15       Impact factor: 5.372

Review 4.  A medicinal chemist's guide to molecular interactions.

Authors:  Caterina Bissantz; Bernd Kuhn; Martin Stahl
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

Review 5.  beta-Secretase as a therapeutic target for Alzheimer's disease.

Authors:  Arun K Ghosh; Sandra Gemma; Jordan Tang
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

6.  Highly Stereoselective Asymmetric Aldol Routes to tert-Butyl-2-(3,5-difluorophenyl)-1-oxiran-2-yl)ethyl)carbamates: Building Blocks for Novel Protease Inhibitors.

Authors:  Arun K Ghosh; Emilio L Cárdenas; Margherita Brindisi
Journal:  Tetrahedron Lett       Date:  2017-09-14       Impact factor: 2.415

Review 7.  The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.

Authors:  Stefania Butini; Simone Brogi; Ettore Novellino; Giuseppe Campiani; Arun K Ghosh; Margherita Brindisi; Sandra Gemma
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 8.  BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

Authors:  Arun K Ghosh; Heather L Osswald
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

9.  AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease.

Authors:  Olivier Descamps; Patricia Spilman; Qiang Zhang; Clare P Libeu; Karen Poksay; Olivia Gorostiza; Jesus Campagna; Barbara Jagodzinska; Dale E Bredesen; Varghese John
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Discovery of potent beta-secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids.

Authors:  Yi-Ping Zhu; Kun Xiao; Hai-Ping Yu; Lan-Ping Ma; Bing Xiong; Hai-Yan Zhang; Xin Wang; Jing-Ya Li; Jia Li; Jing-Kang Shen
Journal:  Acta Pharmacol Sin       Date:  2009-01-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.